Reasons and Factors Contributing to Chinese Patients' Preference for Ustekinumab in Crohn's Disease: A Multicenter Cross-Sectional Study

• Main Authors: Lingya Yao (Author), Xiao Zhu (Author), Bule Shao (Author), Rongbei Liu (Author), Zhilun Li (Author), Lexi Wu (Author), Jin Chen (Author), Qian Cao (Author)
• Format: Book
• Published: Frontiers Media S.A., 2021-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background and Aims: Ustekinumab (UST) was approved in China for treating moderate-to-severe Crohn's disease (CD) in 2020. We aimed to identify the reasons and possible contributing factors for UST preference in Chinese patients with CD.Methods: We conducted a multicenter cross-sectional survey...